- Home
- SQNS vs ABOS Comparison
SQNS vs ABOS Comparison
Compare SQNS & ABOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SQNS
- ABOS
- Stock Information
- Founded
- SQNS 2003
- ABOS 1996
- Country
- SQNS France
- ABOS United States
- Employees
- SQNS N/A
- ABOS N/A
- Industry
- SQNS Semiconductors
- ABOS Biotechnology: Pharmaceutical Preparations
- Sector
- SQNS Technology
- ABOS Health Care
- Exchange
- SQNS Nasdaq
- ABOS Nasdaq
- Market Cap
- SQNS 85.7M
- ABOS 83.5M
- IPO Year
- SQNS 2011
- ABOS 2021
- Fundamental
- Price
- SQNS $2.42
- ABOS $1.39
- Analyst Decision
- SQNS Strong Buy
- ABOS Strong Buy
- Analyst Count
- SQNS 1
- ABOS 3
- Target Price
- SQNS $7.50
- ABOS $9.33
- AVG Volume (30 Days)
- SQNS 106.1K
- ABOS 232.9K
- Earning Date
- SQNS 02-11-2025
- ABOS 03-25-2025
- Dividend Yield
- SQNS N/A
- ABOS N/A
- EPS Growth
- SQNS N/A
- ABOS N/A
- EPS
- SQNS 2.00
- ABOS N/A
- Revenue
- SQNS $36,762,000.00
- ABOS N/A
- Revenue This Year
- SQNS N/A
- ABOS N/A
- Revenue Next Year
- SQNS $95.51
- ABOS N/A
- P/E Ratio
- SQNS $1.21
- ABOS N/A
- Revenue Growth
- SQNS 9.36
- ABOS N/A
- 52 Week Low
- SQNS $0.85
- ABOS $1.28
- 52 Week High
- SQNS $4.28
- ABOS $5.09
- Technical
- Relative Strength Index (RSI)
- SQNS 32.53
- ABOS 37.15
- Support Level
- SQNS $2.47
- ABOS $1.36
- Resistance Level
- SQNS $2.66
- ABOS $1.52
- Average True Range (ATR)
- SQNS 0.21
- ABOS 0.08
- MACD
- SQNS -0.06
- ABOS 0.01
- Stochastic Oscillator
- SQNS 3.96
- ABOS 40.30
About SQNS Sequans Communications S.A.
Sequans Communications SA is a designer, developer, and supplier of cellular semiconductor solutions for broadband Internet of Things (IoT) markets. Its solutions incorporate baseband processor and radio frequency, transceiver integrated circuits, along with its proprietary signal processing techniques, algorithms, and software stacks. The company's solutions serve as the core wireless broadband communications platform in devices, including smartphones, USB dongles, portable routers, laptops, netbooks, tablets, and other consumer multimedia and industrial devices. Its geographical segments are Taiwan, Korea, China (including Hong Kong), the Rest of Asia, the United States and the Rest of the world.
About ABOS Acumen Pharmaceuticals Inc.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.